Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

Highlights • Enzalutamide and abiraterone prolong OS, but resistance is a major clinical problem. • Mechanisms of de novo or acquired resistance can be AR-dependent or AR-independent. • To prevent or overcome resistance, many new agents are currently being tested. • The addition of these drugs may i...

Full description

Saved in:
Bibliographic Details
Published in:Cancer treatment reviews 2015-12, Vol.41 (10), p.884-892
Main Authors: Buttigliero, Consuelo, Tucci, Marcello, Bertaglia, Valentina, Vignani, Francesca, Bironzo, Paolo, Di Maio, Massimo, Scagliotti, Giorgio Vittorio
Format: Article
Language:English
Subjects:
Abiraterone
Androgens - metabolism
Androstenes - therapeutic use
Antineoplastic Agents - therapeutic use
Disease-Free Survival
Drug Resistance, Neoplasm
Enzalutamide
Gene Amplification
Hematology, Oncology and Palliative Medicine
Humans
Male
Mechanisms of resistance
Mutation
Phenylthiohydantoin - analogs & derivatives
Phenylthiohydantoin - therapeutic use
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - genetics
Prostatic Neoplasms, Castration-Resistant - metabolism
Receptors, Androgen - genetics
Receptors, Androgen - metabolism
Receptors, Glucocorticoid - genetics
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Enzalutamide and abiraterone prolong OS, but resistance is a major clinical problem. • Mechanisms of de novo or acquired resistance can be AR-dependent or AR-independent. • To prevent or overcome resistance, many new agents are currently being tested. • The addition of these drugs may improve synergically the efficacy of hormonal therapy.
ISSN:0305-7372
1532-1967
DOI:10.1016/j.ctrv.2015.08.002